Supernus Pharma (SUPN) Misses Q4 EPS by 1c

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.26, $0.01 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $88.4 million versus the consensus estimate of $87.28 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
• Amylyx ALS drug shows no serious adverse events in Phase 1 trial